Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Safety and efficacy of omalizumab in children with allergic asthma

Judy Pitts, Shahid Sheikh, Karen McCoy
European Respiratory Journal 2011 38: p4826; DOI:
Judy Pitts
1Division of Pulmonary Medicine/Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahid Sheikh
2Division of Pulmonary Medicine/Department of Pediatrics, Ohio State University College of Medicine/Nationwide Children's Hospital, Columbus, OH, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen McCoy
2Division of Pulmonary Medicine/Department of Pediatrics, Ohio State University College of Medicine/Nationwide Children's Hospital, Columbus, OH, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Omalizumab (Xolair) is a humanized monoclonal antibody used in the treatment of adults and children over 12 years with moderate to severe allergic asthma. Pediatric studies are few.

Objective: A retrospective chart review of pediatric patients who received omalizumab in the past 10 years for asthma at Nationwide Children's Hospital, Columbus, Ohio.

Results: We had 13 patients, M:F 7:6, median age 13 years (range 9-17), median duration of therapy 36 months (range 1 to 59 months), 9 African American and 4 Caucasian, duration of asthma 15 years (8 to 16). Eight are still on therapy. All patients had severe persistent asthma. Twelve patients were receiving combination therapy (ICS and LABA). Only 4 patients claimed compliance with their asthma controller therapy. Five had family history of asthma, 6 had smoking exposure. Median IgE before starting omalizumab was 249 (range 78 to 2600). Mean BMI was 25.7 and 46% of the patients were above the 100 percentile for BMI. Comparing between one year before and during omalizumab, mean hospital admission/patient/year decreased from 1.7±2.4 to 0.58±1.4 (p<0.05). There was also a trend towards improvement in ED visits from 2.3±3.2 to 1.7±3. Mean FEV1 during one year before omalizumab therapy, at initiation of therapy and during therapy was 91±18, 94±17, and 93±11 and was not statistically different.

Two of 13 patients were taken off omalizumab because of serious side effects, one with anaphylaxis and second with dilated cardiomyopathy. Anaphylaxis was noted on first dose and cardiomyopathy was diagnosed in 5th year on therapy.

Conclusion: Omalizumab is add-on therapy for some patients with allergic asthma. Adverse reactions in children are limiting factor.

  • © 2011 ERS
Previous
Back to top
Vol 38 Issue Suppl 55 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety and efficacy of omalizumab in children with allergic asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safety and efficacy of omalizumab in children with allergic asthma
Judy Pitts, Shahid Sheikh, Karen McCoy
European Respiratory Journal Sep 2011, 38 (Suppl 55) p4826;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Safety and efficacy of omalizumab in children with allergic asthma
Judy Pitts, Shahid Sheikh, Karen McCoy
European Respiratory Journal Sep 2011, 38 (Suppl 55) p4826;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Designing a holding chamber mask using anthropometric data and CAD-simulation
  • Breath-by-breath delivered dose comparison from three anti-static valved holding chambers with facemasks under simulated pediatric breathing conditions
  • Did inappropriate delivery systems hamper therapeutic efficacy of di-sodium-cromo-glycate (DSCG)? Time for a reappraisal
Show more 495. Treating childhood asthma

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society